Life-threatening hyponatremia caused by vinblastine

Med Oncol Tumor Pharmacother. 1988;5(1):67-9. doi: 10.1007/BF03003183.

Abstract

Some days after the administration of a third bolus of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) a patient affected by immunoblastic lymphoma underwent a neurotoxic crisis. The episode lasted 1 week and was followed by a dramatic fall in plasma sodium (104 mEq I-1), associated with a proportionally lesser decrease in plasma chloride and phosphate. Despite the lowest plasma osmolality, detectable levels of circulating ADH were present. After 36 h the hyponatremic episode improved after the infusion of hypertonic sodium chloride. Nevertheless the patient lapsed into a hypotonic coma. The urinary concentrations of the main tubular enzymes (gamma-glutamyltranspeptidase, N-acetyl-glucosaminidase, alpha-glucosidase) proved very high and successively decreased slowly. The most likely cause of such hyponatremic episode is vinblastine. The drug acted through: (a) an already known inappropriate release of ADH, and (b) a hitherto unreported tubular lesion, which impaired the reabsorption of sodium and other coupled solutes.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / administration & dosage
  • Dacarbazine / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Hyponatremia / chemically induced*
  • Kidney Tubules / drug effects
  • Lymphoma, Non-Hodgkin / drug therapy
  • Vasopressins / blood
  • Vinblastine / adverse effects*
  • Vincristine / administration & dosage

Substances

  • Vasopressins
  • Bleomycin
  • Vincristine
  • Vinblastine
  • Dacarbazine
  • Doxorubicin

Supplementary concepts

  • ABVD protocol